6.1 FDCA, Adulteration, and Misbranding

Why federal drug law still sits on the CT MPJE

Quick Answer: The Federal Food, Drug, and Cosmetic Act (FDCA) of 1938 is the national floor. Adulteration (21 U.S.C. § 351) means something is wrong with the article or the conditions under which it was made, packed, or held—expired tablets in the active bay. Misbranding (21 U.S.C. § 352) means something is wrong with the labeling—wrong name, wrong SIG, missing Rx legend. Durham-Humphrey (1951) created Rx versus OTC; Kefauver-Harris (1962) added efficacy. Compounding that exceeds § 503A is treated as an unapproved new drug that is both adulterated and misbranded.

Connecticut pharmacies practice under two statutes at once. NABP Area 2.5 still tests the FDCA because a Hartford pharmacist who only memorizes Chapter 400j will miss adulteration, misbranding, and compounding traps that FDA—not DCP—wrote. Connecticut Chapters 417 and 418 create state food-and-drug analogs; they do not waive 21 U.S.C. §§ 351 and 352. When the two differ, Connecticut may be stricter; more-restrictive wins.

The 1938 Act and the two amendments the exam quotes

Congress enacted the FDCA in 1938 after Elixir Sulfanilamide, in which diethylene glycol killed more than 100 people. The 1938 statute required manufacturers to demonstrate safety before marketing a new drug. It did not yet require proof of efficacy, and it did not draw a clean line between prescription and over-the-counter products.

Memorize the years with the verbs:

• 1938 FDCA — premarket safety (new-drug application); no efficacy showing yet; no clean Rx/OTC split
• Durham-Humphrey Amendment of 1951 (FDCA § 503(b), 21 U.S.C. § 353(b)) — modern Rx versus OTC classes; authorized oral prescriptions and refills; an Rx-only drug dispensed without a valid prescription is misbranded. The historic caution statement ('Caution: Federal law prohibits dispensing without a prescription') was later shortened to 'Rx only' by the FDA Modernization Act of 1997.
• Kefauver-Harris Amendments of 1962 — after thalidomide, substantial evidence of effectiveness as well as safety; informed consent for investigational use; adverse-event reporting; FDA control of prescription-drug advertising. A product marketed for a use never shown effective can be both an unapproved new drug and misbranded.

A drug must be dispensed only on prescription if, because of toxicity, method of use, or collateral measures, it is not safe for use except under the supervision of a licensed practitioner, or if approved labeling limits it to prescription use. Moving a molecule from Rx to OTC is an FDA decision, not a Commission of Pharmacy vote.

Adulteration (FDCA § 501 / 21 U.S.C. § 351)

A drug is adulterated when something is wrong with the article itself or with the conditions under which it was made, packed, or held. High-yield federal triggers include:

• It consists in whole or in part of any filthy, putrid, or decomposed substance
• It has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated or rendered injurious to health
• The methods, facilities, or controls do not conform to current good manufacturing practice (CGMP)
• Its strength differs from, or its quality or purity falls below, the official USP/NF standard—or, if it is not a compendial drug, below what it purports to possess
• A substance has been mixed or packed with it so as to reduce quality or strength, or substituted for it

Pharmacy examples the exam likes:

• Expired tablets sitting in the active dispensing bay. Once the labeled expiration date has passed, strength, quality, or purity can no longer be assured. Keeping that stock available for filling is a classic adulteration fact pattern even if the bottle looks clean and the foil is intact.
• A reconstituted antibiotic stored at room temperature after the label required refrigeration, or a vial with visible particulate matter.
• Compounding performed at a dirty sink, with non-pharmaceutical-grade bulk, or in a way that fails 503A conditions so that CGMP exemptions no longer apply.

Adulteration is about the product and the process. A perfectly worded label does not clean an expired or contaminated bottle.

Misbranding (FDCA § 502 / 21 U.S.C. § 352)

A drug is misbranded when something is wrong with the labeling, the representation, or the required statements—not (primarily) with the chemistry. Section 352 deems a drug misbranded if, among other things:

• Its labeling is false or misleading in any particular
• It is in package form and lacks the name and place of business of the manufacturer, packer, or distributor, or an accurate statement of quantity
• Required information is not prominently placed
• It lacks adequate directions for use, or adequate warnings
• It is a prescription drug dispensed without the required Rx legend / 'Rx only', or an OTC drug that wears a prescription legend it should not wear
• It is an imitation of another drug, or offered for sale under the name of another drug

Labeling is broader than the container label. It includes the package insert, Medication Guide, and any written, printed, or graphic matter accompanying the drug.

Pharmacy examples:

• A vial labeled 'amoxicillin 500 mg' that actually contains 250 mg tablets is both adulterated (strength) and misbranded (false labeling)
• A correctly filled prescription released with the wrong patient name, the wrong directions, a missing strength, or a missing pharmacy identifier is misbranded at the dispensed-container level
• Selling an Rx-only product OTC, or leaving the manufacturer's stock bottle on the shelf with a homemade sticker that claims an unapproved use

Adulteration versus misbranding at the Connecticut counter

Compounding that exceeds 503A

Title I of the Drug Quality and Security Act (DQSA, 2013) left traditional pharmacy compounding in FDCA § 503A (21 U.S.C. § 353a). A licensed pharmacist in a state-licensed pharmacy (or a licensed physician) who compounds for an identified individual patient pursuant to a valid prescription—or in limited quantity in anticipation of that prescription—can be exempt from CGMP (§ 501(a)(2)(B)), adequate-directions labeling (§ 502(f)(1)), and new-drug approval (§ 505). Conditions include using appropriate bulk substances, not compounding drugs withdrawn for safety or efficacy, not compounding regularly or in inordinate amounts essentially copies of commercially available products, and respecting interstate-distribution limits.

When a Connecticut pharmacy steps outside those conditions—office-use batches without a 503B registration, copies of an available tablet 'because the clinic likes our base,' or compounding a drug on FDA's withdrawn list—the exemptions vanish. FDA then treats the products as unapproved new drugs that are adulterated (no CGMP) and misbranded (no adequate directions). Chapter 17 covers USP <795>/<797> and RCSA compounding. Here, know that exceeding 503A is an FDCA quality-and-labeling problem, not merely a state-board issue.

Scenario: two sections, one afternoon

A Waterbury pharmacist finds a tray of expired hydrochlorothiazide still in the robot's active canisters and, the same afternoon, releases a correctly selected lisinopril vial with a label that lists the neighbor's name. Two different FDCA sections fire. The expired stock is adulterated under § 351 even if no patient has received it yet. The mislabeled vial is misbranded under § 352 even if the tablets inside are the right strength and in date. Pulling the expired canisters and relabeling the vial are both required; arguing 'FDA only cares about manufacturers' is not a defense. DCP Drug Control can cite the same facts under Connecticut's food-and-drug chapters.

Connecticut Chapters 417 and 418 and DCP inspection authority sit on top of this floor. CT may be stricter; more-restrictive wins.

Official anchors

• 21 U.S.C. § 351 — adulterated drugs and devices (FDCA § 501).
• 21 U.S.C. § 352 — misbranded drugs and devices (FDCA § 502).
• FDA 503A / 503B comparison — when compounding loses CGMP, labeling, and new-drug exemptions.